John Turman Fleming, who serves as a director at USANA Health Sciences Inc. (NASDAQ:USNA), executed a transaction involving his company's common stock on June 1, 2026. The specific sale involved the disposition of 2,450 shares at an agreed-upon price of $17.93 per share, resulting in total proceeds of $43,928.
As of recent trading, USNA's common stock trades at $18.33. This current valuation represents a notable decline of 38.73% over the past year and situates the stock near its five-two-week low point of $16.60.
Director Holdings and Valuation Context
Following this reported sale, Mr. Fleming's remaining direct holding in USANA common stock totals 4,230 shares. This insider activity is observed while external data suggests the company may be undervalued when compared to its calculated Fair Value. Furthermore, one source noted an impressive gross profit margin of 77.55% for the enterprise.
In related analysis, investor insights point out that management has recently engaged in aggressive share repurchase activities. For a more thorough understanding of USANA's financial standing and competitive positioning, comprehensive research reports are available covering this stock and over 1,400 other U.S. equities.
Recent Corporate Performance Highlights
Beyond the insider trading reports, USANA Health Sciences recently released financial results for the first quarter of 2026. These figures indicated a strong performance, surpassing both analyst expectations for earnings and revenue.
Specifically, the company reported earnings per share (EPS) of $0.61. This figure significantly exceeded the anticipated estimate of $0.40, marking an impressive surprise margin of 52.5%. On the top line, revenue reached $250 million. This amount surpassed the forecasted revenue expectation of $240.95 million.
Furthermore, USANA Health Sciences conducted its annual meeting of shareholders. During this gathering, representation was noted from approximately 89% of all issued and outstanding shares. At this meeting, shareholders elected eight directors to serve on the board for the upcoming year. Among those newly elected were Kevin G. Guest and Xia Ding.
These developments collectively suggest ongoing strategic efforts and a positive financial trajectory for the company as it moves forward.